Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites


Aims: To explore efficacy and side effects of intrapleural or intraperitoneal lobaplatin for treating patientswith malignant pleural or peritoneal effusions.
Methods: Patients in Jiangsu Cancer Hospital and ResearchInstitute with cytologically confirmed solid tumors complicated with malignant pleural effusion or ascites wereenrolled into this study. Lobaplatin (20-30 mg/m2) was intrapleurally or intraperitoneally infused for patientswith malignant pleural effusion or ascites.
Results: From 2012 to 2013, intrapleural or intraperitonea lobaplatinwas administered for patients with colorectal or uterus cancer who were previous treated for malignant pleuraleffusion or ascites. Partial response was achieved for them. Main side effects were nausea/vomiting, and bonemarrow suppression. No treatment related deaths occurred.
Conclusion: Intrapleural or intraperitoneal infusionof lobaplatin is a safe treatment for patients with malignant pleural effusion or ascites, and the treatment efficacyis encouraging.